Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3977 | The demographic, clinical, laboratory, and instrumental data Wiki | 0.71 |
| drug2586 | No interventions planned Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018352 | Coronavirus Infections NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
The purpose of this study is to evaluate the sensitivity and specificity of several marketed commercial or prototype test kits for antibody to SARS-CoV-2. The focus will be on rapid-format, point-of-care antibody test kits that detect both IgM and IgG antibodies to recombinant viral proteins. Note: No voluntary enrolment into this study will be conducted; all testing is to be conducted anonymously.
Description: Test sensitivity relative to RT-PCR for acute samples; sensitivity relative to ELISA for convalescent samples.
Measure: Test Sensitivity Time: 2020Description: Percent positivity with pre-COVID samples
Measure: Test Specificity Time: 2020This is a prospective, longitudinal study to determine the incidence of SARS-COV-2 infection in children and adolescents by measuring specific antibodies in non-invasive saliva sampled in kindergartens and schools in a defined city area. The study includes an additional arm to validate the ELISA for anti-SARS-COV-2 reactive antibody measurements in saliva compared against blood collected in adult volunteers in a bimonthly follow-up period for 12 months.
Description: Identification of children that have been infected over different periods of time (summer, before winter and after winter) based on saliva samples
Measure: Incidence of SARS-CoV-2 infection in infants, children and adolescents Time: 12 monthsDescription: Change of incidence of SARS-CoV-2 infection in children during 2020/2021
Measure: Incidence of SARS-CoV-2 Time: 12 monthsDescription: SARS-CoV-2 antibodies persistence in peripheral blood and saliva
Measure: SARS-CoV-2 antibody persistence Time: 12 monthsDescription: Saliva samples as alternative for the detection of antibodies against SARS-CoV-2
Measure: Antibodies presence in saliva samples Time: 18 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports